The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.
Not Applicable
- Conditions
- Secondary osteoporosis
- Registration Number
- JPRN-UMIN000009182
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1. Using other osteoporosis drugs except alfacalcidol within 6 months. 2. Patients suffered from malignancies except mammary carcinoma. 3. Patients with contraindication for eldecalcitol treatments 4. Patients who have serum calcium levels of above 10.4mg/dL. 5. Patients judged inappropriate by attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method